Clinical Trials
Advancing novel candidates with the highest likelihood of driving significant benefit for patients.
We’re committed to evolving immunology. Our pipeline includes programs that are targeted to address highly prevalent inflammatory diseases. Our goal is to drive meaningful advances for patients with these diseases, designing all our programs to deliver best-in-class profiles.
EVO756-CIU001 is a Phase 2a, multi-center, open-label, within-subject controlled study evaluating EVO756 in adults with chronic inducible urticaria (either cold urticaria or symptomatic dermographism). All participants will receive EVO756, daily for a four-week treatment period. Patients will be evaluated for safety and efficacy at weekly visits during treatment and return to the clinic for final assessments two weeks following the last dose of study drug.
For additional information about the trial, please visit clinicaltrials.gov using the identifier NCT06603220.
EVO756-CSU001 is a Phase 2b, randomized, placebo-controlled, multi-center study assessing EVO756, at multiple doses, in adults with chronic spontaneous urticaria. Participants will receive EVO756 or placebo for a 12-week treatment period and be evaluated for safety and efficacy at the clinical study site during the treatment period. Patients will return to the clinic for final assessments 2 weeks following the last dose of study drug.
For additional information about the trial, please visit clinicaltrials.gov using the identifier NCT06873516.
EVO301-AD001 is a Phase 2a, randomized, placebo-controlled, multi-center study evaluating EVO301 in adults with atopic dermatitis. Patients will be administered two intravenous treatments of EVO301 or placebo and followed for safety and efficacy over a 12-week study period.
For additional information about the trial, please visit clinicaltrials.gov using the identifier NCT06723405.